The writing was on the wall when Fraunhofer declared that the trial had been enrolled to the point statistically necessary and the last 17 SOC/placebo patients were deliberately kept out of the trial thus weakening its overall powering even while the remaining 31-32 treatment arm patients were enrolled. The exclamation point came with the JAMA peer reviewed article which validated the reason for the GERMAN SOC/placebo participation being withheld at the end of the trial enrollment period. You see, the Germans do not allow for patients to be enrolled in a KNOWN lesser treatment regimen for the sake of experimentation. THAT gives real meaning to the trial screening and SOC/placebo enrollment hold. This is why longs aren’t willing to wear the blinders you offer; ). Maybe YOU are the one who should reconsider YOUR accusations and assumptions before they chase YOU down and make YOU pay; ). Best wishes.
Market Data 
Markets 
AI
